Zai Lab Ltd. Awaits Results from FORTITUDE-102 Trial for Bemarituzumab in Gastric Cancer Treatment Following Attenuated Survival Benefit in Phase 3 FORTITUDE-101 Study
Reuters
Sep 03
<a href="https://laohu8.com/S/ZAILF">Zai Lab</a> Ltd. Awaits Results from FORTITUDE-102 Trial for Bemarituzumab in Gastric <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a> Following Attenuated Survival Benefit in Phase 3 FORTITUDE-101 Study
Zai Lab Ltd. has announced an update on Amgen's Phase 3 FORTITUDE-101 study evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) for first-line gastric cancer treatment. The final analysis of the trial has been completed, revealing that while the bemarituzumab plus chemotherapy regimen initially demonstrated a clinically and statistically significant improvement in overall survival compared to chemotherapy alone, the magnitude of this survival benefit has lessened in the final analysis. The results from both the interim and final analyses are slated to be presented at an upcoming major medical meeting. Zai Lab plans to await the results of the FORTITUDE-102 study, which is evaluating bemarituzumab in combination with nivolumab and chemotherapy in the same patient population, before proceeding with regulatory filings. The data readout from FORTITUDE-102 is expected by the end of 2025 or the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.